Literature DB >> 29260281

Uncommon evolutions and complications of common benign liver lesions.

Federica Vernuccio1,2, Maxime Ronot3, Marco Dioguardi Burgio3, Jérôme Lebigot4, Wassim Allaham3, Christophe Aubé4, Giuseppe Brancatelli5, Valérie Vilgrain3.   

Abstract

Frequently encountered on abdominal imaging studies, the majority of common benign liver lesions are asymptomatic, confidently diagnosed by imaging, and do not require further workup, follow-up, or treatment. The increasing use of multimodality liver imaging, has allowed the recognition of uncommon evolutions of common benign liver lesions such as size changes, fibrotic regression, and content and vascularization changes, and their complications such as rupture, hemorrhage, thrombosis, extrinsic compression, and malignancy. The purpose of this pictorial review is to describe and illustrate the incidence and diagnostic features of these uncommon evolutions and complications on cross-sectional imaging, mainly on computed tomography and magnetic resonance imaging, with emphasis on those imaging clues which are helpful in the differential diagnosis or indicate the need for treatment.

Entities:  

Keywords:  Benign liver lesions; Complications; Computed tomography; Magnetic resonance imaging; Uncommon evolutions

Mesh:

Year:  2018        PMID: 29260281     DOI: 10.1007/s00261-017-1427-6

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  2 in total

Review 1.  Hepatic tumors: pitfall in diagnostic imaging.

Authors:  Giulia Grazzini; Diletta Cozzi; Federica Flammia; Roberta Grassi; Andrea Agostini; Maria Paola Belfiore; Alessandra Borgheresi; Maria Antonietta Mazzei; Chiara Floridi; Gianpaolo Carrafiello; Andrea Giovagnoni; Silvia Pradella; Vittorio Miele
Journal:  Acta Biomed       Date:  2020-07-13

2.  Bland Embolization of Benign Liver Tumors: Review of the Literature and a Single Center Experience.

Authors:  Daniel Crawford; Sailen Naidu; Indravadan Patel; Grace Knuttinen; Sadeer Alzubaidi; Rahmi Oklu
Journal:  J Clin Med       Date:  2021-02-09       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.